Immunologi:
Våre andre terapiområder

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}
      • div
      SELECT-EARLY

        

      div

      The study evaluated 2 doses of upadacitinib, 15 mg and 30 mg QD. The results presented here are for RINVOQ (upadacitinib) 15 mg once daily, which is the approved dose for Rheumatoid Arthritis.

      SELECT-EARLY: Study design

      A Phase 3 study investigating the efficacy and safety of RINVOQ monotherapy compared with MTX in MTX-naive patients with moderately to severely active RA1

      Primary
      RINVOQ 15 mg vs MTX for DAS28 (CRP) <2.6 at Week 24 or ACR50 at Week 12 

      Safety
      Adverse events, serious adverse events, adverse event of special interest (e.g., serious infections, opportunistic infections, MACEs, VTEs, malignancies)

      ACR: American College of Rheumatology; ACR50: improvement of at least 50% in the American College of Rheumatology core criteria; CDAI: Clinical Disease Activity Index; DAS28 (CRP): disease activity score with 28 joint count (C-reactive protein); JAK: Janus kinase; MACE: major adverse cardiovascular events; MTX: methotrexate; QD: once daily; VTE: venous thromboembolic event.

      div

      RINVOQ monotherapy data

      SELECT-EARLY: Remission (primary endpoint) and low disease activity at Week 24 in MTX-naive patients1*

      *RINVOQ is not indicated for MTX-naive patients. 
      † P<0.001 vs MTX 

      DAS28 (CRP): disease activity score with 28 joint counts (C-reactive protein); MTX: methotrexate.

      div

      Joint protection with RINVOQ monotherapy 

      SELECT-EARLY: Inhibition of structural joint damage progression as monotherapy in MTX-naive patients* at Week 241

       

      Change in mTSS for RINVOQ vs MTX at Week 24 was a ranked secondary endpoint controlled for multiplicity. All other data shown for RINVOQ vs MTX were prespecified nonranked endpoints not controlled for multiplicity; nominal P-values are provided.

      *RINVOQ is not indicated for MTX-naive patients.
      † P≤0.01 vs MTX
      ||Indicates multiplicity-controlled comparison of RINVOQ vs MTX.

       mTSS: modified total Sharp score; MTX:methotrexate.



      div

      Jeg vil gjerne ha mer informasjon fra en produktspesialist.

      Mer info

      Jeg har spørsmål til medisinsk avdeling.

      Mer info

      Felleskatalogteksten finner du her

      Felleskatalogtekst

      Referanser

      1. RINVOQ SPC avsnitt 5.1, sist oppdatert 21.05.2021.

       

      NO-RNQ-200013v2.0juni/2021